## John M Luk

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5422192/publications.pdf

Version: 2024-02-01

189	13,812	59 h-index	112
papers	citations		g-index
191	191	191	18992 citing authors
all docs	docs citations	times ranked	

#	Article	lF	Citations
1	Clinical correlation of cadherinâ€17 marker with advanced tumor stages and poor prognosis of cholangiocarcinoma. Journal of Surgical Oncology, 2021, 123, 1253-1262.	1.7	5
2	Cadherin-17 Targeted Near-Infrared Photoimmunotherapy for Treatment of Gastrointestinal Cancer. Molecular Pharmaceutics, 2020, 17, 3941-3951.	4.6	16
3	Using Simulation to Teach Interprofessional Communication in Palliative Care (FR482A). Journal of Pain and Symptom Management, 2019, 57, 437-438.	1.2	O
4	A single H/ACA small nucleolar RNA mediates tumor suppression downstream of oncogenic RAS. ELife, 2019, 8, .	6.0	89
5	Development of anti-cadherin-17 antibody -IR700 conjugate for photodynamic therapy against gastrointestinal cancers. , 2019, , .		1
6	Serine peptidase inhibitor Kazal type 1 (SPINK1) as novel downstream effector of the cadherin- $17/\hat{1}^2$ -catenin axis in hepatocellular carcinoma. Cellular Oncology (Dordrecht), 2017, 40, 443-456.	4.4	13
7	Operationalizing Interprofessional Education in the Clinical Workplace. Medical Science Educator, 2017, 27, 753-758.	1.5	5
8	Integrin $\hat{l}\pm2\hat{l}^21$ inhibits MST1 kinase phosphorylation and activates Yes-associated protein oncogenic signaling in hepatocellular carcinoma. Oncotarget, 2016, 7, 77683-77695.	1.8	53
9	Professional Identity Formation. Academic Medicine, 2015, 90, 761-767.	1.6	118
10	Targeting Hippo pathway by specific interruption of YAPâ€₹EAD interaction using cyclic YAPâ€like peptides. FASEB Journal, 2015, 29, 724-732.	0.5	115
11	Circulating mortalin autoantibody—a new serological marker of liver cirrhosis. Cell Stress and Chaperones, 2015, 20, 715-719.	2.9	7
12	SOD2 rs4880 CT/CC genotype predicts poor survival for Chinese gastric cancer patients received platinum and fluorouracil based adjuvant chemotherapy. American Journal of Translational Research (discontinued), 2015, 7, 401-10.	0.0	11
13	miR-122 Targets Pyruvate Kinase M2 and Affects Metabolism of Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e86872.	2.5	109
14	Dysregulated expression of dickkopfs for potential detection of hepatocellular carcinoma. Expert Review of Molecular Diagnostics, 2014, 14, 535-548.	3.1	16
15	Diverse modes of genomic alteration in hepatocellular carcinoma. Genome Biology, 2014, 15, 436.	8.8	100
16	Genomic Predictors for Recurrence Patterns of Hepatocellular Carcinoma: Model Derivation and Validation. PLoS Medicine, 2014, 11, e1001770.	8.4	117
17	miRNAs: new tools for molecular classification, diagnosis and prognosis of hepatocellular carcinoma. Hepatic Oncology, 2014, 1, 323-329.	4.2	4
18	Prognostic Marker MicroRNA-125b Inhibits Tumorigenic Properties of Hepatocellular Carcinoma Cells Via Suppressing Tumorigenic Molecule eIF5A2. Digestive Diseases and Sciences, 2014, 59, 2477-2487.	2.3	42

#	Article	IF	CITATIONS
19	Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo. Molecular Cancer, 2014, 13, 66.	19.2	151
20	An alternative DNA damage pathway to apoptosis in hematological cancers. Nature Medicine, 2014, 20, 587-588.	30.7	5
21	Targeting Cancer Metabolisms. , 2013, , 159-174.		0
22	Circulating markers for prognosis of hepatocellular carcinoma. Expert Opinion on Medical Diagnostics, 2013, 7, 319-329.	1.6	22
23	Oncofetal Gene <i>SALL4</i> in Aggressive Hepatocellular Carcinoma. New England Journal of Medicine, 2013, 368, 2266-2276.	27.0	223
24	Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma. Oncology Reports, 2013, 29, 840-846.	2.6	75
25	Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Research, 2013, 23, 1422-1433.	<b>5.</b> 5	457
26	Anti-Cadherin-17 Antibody Modulates Beta-Catenin Signaling and Tumorigenicity of Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e72386.	2.5	18
27	MicroRNA as Cancer Biomarkers and Targets. , 2013, , 39-56.		0
28	Celastrol Suppresses Growth and Induces Apoptosis of Human Hepatocellular Carcinoma through the Modulation of STAT3/JAK2 Signaling Cascade <i>In Vitro</i> and <i>In Vivo</i> Cancer Prevention Research, 2012, 5, 631-643.	1.5	146
29	An update on targeting Hippo-YAP signaling in liver cancer. Expert Opinion on Therapeutic Targets, 2012, 16, 243-247.	3.4	29
30	A morpho-molecular prognostic model for hepatocellular carcinoma. British Journal of Cancer, 2012, 107, 334-339.	6.4	26
31	Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open, 2012, 2, e000825.	1.9	206
32	Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nature Genetics, 2012, 44, 765-769.	21.4	785
33	Dickkopf 4 (DKK4) acts on Wnt/l²-catenin pathway by influencing l²-catenin in hepatocellular carcinoma. Oncogene, 2012, 31, 4233-4244.	5.9	48
34	Discovery of Lamin B1 and Vimentin as Circulating Biomarkers for Early Hepatocellular Carcinoma. , 2012, 909, 295-310.		18
35	Prognostic significance of phosphorylated RON in esophageal squamous cell carcinoma. Medical Oncology, 2012, 29, 1699-1706.	2.5	10
36	Clinical correlation of nuclear survivin in esophageal squamous cell carcinoma. Medical Oncology, 2012, 29, 3009-3016.	2.5	11

#	Article	IF	Citations
37	Interleukin 23 Promotes Hepatocellular Carcinoma Metastasis via NF-Kappa B Induced Matrix Metalloproteinase 9 Expression. PLoS ONE, 2012, 7, e46264.	2.5	68
38	Clinical significance of <i>SOD2</i> and <i>GSTP1</i> gene polymorphisms in Chinese patients with gastric cancer. Cancer, 2012, 118, 5489-5496.	4.1	43
39	<i>Tripterygium wilfordii</i> bioactive compounds as anticancer and antiâ€inflammatory agents. Clinical and Experimental Pharmacology and Physiology, 2012, 39, 311-320.	1.9	117
40	Regulators of mammalian Hippo pathway in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1826, 357-364.	7.4	46
41	Cytoplasmic Forkhead Box M1 (FoxM1) in Esophageal Squamous Cell Carcinoma Significantly Correlates with Pathological Disease Stage. World Journal of Surgery, 2012, 36, 90-97.	1.6	33
42	Mortalin-p53 Interaction as a Target for Liver Cancer Therapy. , 2012, , 267-278.		1
43	Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World Journal of Gastroenterology, 2012, 18, 3923.	3.3	96
44	Genetic Biomarkers for the Diagnosis and Prognosis of Hepatocellular Carcinoma. , 2012, , 331-348.		0
45	Predictive Genes in Adjacent Normal Tissue Are Preferentially Altered by sCNV during Tumorigenesis in Liver Cancer and May Rate Limiting. PLoS ONE, 2011, 6, e20090.	2.5	68
46	Interleukin 17A Promotes Hepatocellular Carcinoma Metastasis via NF-kB Induced Matrix Metalloproteinases 2 and 9 Expression. PLoS ONE, 2011, 6, e21816.	2.5	168
47	Quantitative analysis of the expression of TGF-alpha and EGFR in papillary thyroid carcinoma: clinicopathological relevance. Pathology, 2011, 43, 40-47.	0.6	15
48	Serum soluble E-cadherin is a potential prognostic marker in esophageal squamous cell carcinoma. Ecological Management and Restoration, 2011, 24, 49-55.	0.4	19
49	Clinicopathological and prognostic significance of serum and tissue <scp>Dickkopfâ€4</scp> levels in human hepatocellular carcinoma. Liver International, 2011, 31, 1494-1504.	3.9	127
50	AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene, 2011, 30, 1229-1240.	5.9	200
51	Mortalin–p53 interaction in cancer cells is stress dependent and constitutes a selective target for cancer therapy. Cell Death and Differentiation, 2011, 18, 1046-1056.	11.2	143
52	Clinicopathologic and gene expression parameters predict liver cancer prognosis. BMC Cancer, 2011, 11, 481.	2.6	9
53	Induction of mutant p53â€dependent apoptosis in human hepatocellular carcinoma by targeting stress protein mortalin. International Journal of Cancer, 2011, 129, 1806-1814.	5.1	65
54	DLK1-DIO3 Genomic Imprinted MicroRNA Cluster at 14q32.2 Defines a Stemlike Subtype of Hepatocellular Carcinoma Associated with Poor Survival. Journal of Biological Chemistry, 2011, 286, 30706-30713.	3.4	147

#	Article	IF	Citations
55	Dickkopfs and Wnt/l²-catenin signalling in liver cancer. World Journal of Clinical Oncology, 2011, 2, 311.	2.3	54
56	Two-tiered Approach Identifies a Network of Cancer and Liver Disease-related Genes Regulated by miR-122. Journal of Biological Chemistry, 2011, 286, 18066-18078.	3.4	54
57	Proteomics of Hepatocellular Carcinoma in Chinese Patients. OMICS A Journal of Integrative Biology, 2011, 15, 261-266.	2.0	16
58	Global Regulation on microRNA in Hepatitis B Virus-Associated Hepatocellular Carcinoma. OMICS A Journal of Integrative Biology, 2011, 15, 187-191.	2.0	36
59	Gene Signatures Derived from a c-MET-Driven Liver Cancer Mouse Model Predict Survival of Patients with Hepatocellular Carcinoma. PLoS ONE, 2011, 6, e24582.	2.5	26
60	Antibody Therapies for Liver Malignancy and Transplantation. , 2010, , 13-30.		0
61	Enhanced Detection of Early Hepatocellular Carcinoma by Serum SELDI-TOF Proteomic Signature Combined with Alpha-Fetoprotein Marker. Annals of Surgical Oncology, 2010, 17, 2518-2525.	1.5	48
62	Prognostic significance and therapeutic potential of eukaryotic translation initiation factor 5A (eIF5A) in hepatocellular carcinoma. International Journal of Cancer, 2010, 127, 968-976.	5.1	60
63	HNF1α and CDX2 transcriptional factors bind to cadherinâ€₹7 (CDH17) gene promoter and modulate its expression in hepatocellular carcinoma. Journal of Cellular Biochemistry, 2010, 111, 618-626.	2.6	24
64	Activation of interleukin-6-induced glycoprotein 130/signal transducer and activator of transcription 3 pathway in mesenchymal stem cells enhances hepatic differentiation, proliferation, and liver regeneration. Liver Transplantation, 2010, 16, 1195-1206.	2.4	44
65	Targeting YAP and Hippo signaling pathway in liver cancer. Expert Opinion on Therapeutic Targets, 2010, 14, 855-868.	3.4	85
66	microRNAâ€122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Molecular Systems Biology, 2010, 6, 402.	7.2	169
67	MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochemical and Biophysical Research Communications, 2010, 394, 623-627.	2.1	236
68	Role of cadherin-17 in oncogenesis and potential therapeutic implications in hepatocellular carcinoma. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1806, 138-145.	7.4	30
69	Circulating Lamin B1 (LMNB1) Biomarker Detects Early Stages of Liver Cancer in Patients. Journal of Proteome Research, 2010, 9, 70-78.	3.7	111
70	Proteomics of Hepatocellular Carcinoma: Serum Vimentin As a Surrogate Marker for Small Tumors (â‰ <b>2</b> cm). Journal of Proteome Research, 2010, 9, 1923-1930.	3.7	70
71	Prophylactic uses of integrin CD18- $\hat{l}^2$ A peptide in a murine polymicrobial peritonitis model. World Journal of Gastroenterology, 2010, 16, 2648.	3.3	3
72	Hepatic tight junctions: From viral entry to cancer metastasis. World Journal of Gastroenterology, 2010, 16, 289.	3.3	31

#	Article	IF	Citations
73	Role of LPS/CD14/TLR4-mediated inflammation in necrotizing enterocolitis: Pathogenesis and therapeutic implications. World Journal of Gastroenterology, 2009, 15, 4745.	3.3	53
74	A protein-based set of reference markers for liver tissues and hepatocellular carcinoma. BMC Cancer, 2009, 9, 309.	2.6	17
75	Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters. BMC Cancer, 2009, 9, 389.	2.6	111
76	Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology, 2009, 50, 1453-1463.	7.3	107
77	Yesâ€associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer, 2009, 115, 4576-4585.	4.1	438
78	Laparoscopic surgery induced interleukin-6 levels in serum and gut mucosa: implications of peritoneum integrity and gas factors. Surgical Endoscopy and Other Interventional Techniques, 2009, 23, 370-376.	2.4	15
79	Intracellular levels of hepatitis B virus DNA and pregenomic RNA in peripheral blood mononuclear cells of chronically infected patients. Journal of Viral Hepatitis, 2009, 16, 104-112.	2.0	26
80	Proteomic Expression Signature Distinguishes Cancerous and Nonmalignant Tissues in Hepatocellular Carcinoma. Journal of Proteome Research, 2009, 8, 1293-1303.	3.7	60
81	Corrigendum to "96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B― Journal of Hepatology, 2009, 50, 1283-1284.	3.7	0
82	Heat Shock Proteins in Cancer: Signaling Pathways, Tumor Markers and Molecular Targets in Liver Malignancy. Protein and Peptide Letters, 2009, 16, 508-516.	0.9	17
83	Biomarkers for Early Detection of Liver Cancer: Focus on Clinical Evaluation. Protein and Peptide Letters, 2009, 16, 473-478.	0.9	8
84	Editorial [Hot Topic: Proteome/Protein/Peptide in Molecular Medicine (Guest Editor: John M. Luk). Protein and Peptide Letters, 2009, 16, 457-459.	0.9	0
85	The Use of Small Peptides in the Diagnosis and Treatment of Hepatocellular Carcinoma. Protein and Peptide Letters, 2009, 16, 530-538.	0.9	5
86	Proteomic Identification of a Monoclonal Antibody Recognizing Caveolin-1 in Hepatocellular Carcinoma with Metastatic Potential. Protein and Peptide Letters, 2009, 16, 479-485.	0.9	5
87	Endotoxin-Neutralizing Peptides as Gram-Negative Sepsis Therapeutics. Protein and Peptide Letters, 2009, 16, 539-542.	0.9	10
88	Systemic inflammatory response after natural orifice translumenal surgery: transvaginal cholecystectomy in a porcine model. Journal of the Society of Laparoendoscopic Surgeons, 2009, 13, 9-13.	1.1	14
89	Comparative proteomic analysis of mouse livers from embryo to adult reveals an association with progression of hepatocellular carcinoma. Proteomics, 2008, 8, 2136-2149.	2.2	33
90	Toward the proteomic identification of biomarkers for the prediction of HBV related hepatocellular carcinoma. Journal of Cellular Biochemistry, 2008, 103, 740-752.	2.6	39

#	Article	IF	CITATIONS
91	A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nature Genetics, 2008, 40, 623-630.	21.4	514
92	IMMUNOCHEMICAL CHARACTERIZATION OF THE FUNCTIONAL CONSTITUENTS OF <i>TRIPTERYGIUM WILFORDII</i> Pharmacology and Physiology, 2008, 35, 55-59.	1.9	18
93	The potential clinical relevance of serum vascular endothelial growth factor (VEGF) and VEGF-C in recurrent papillary thyroid carcinoma. Surgery, 2008, 144, 934-941.	1.9	36
94	96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. Journal of Hepatology, 2008, 48, 714-720.	3.7	63
95	Refinement of the basis and impact of common 11q23.1 variation to the risk of developing colorectal cancer. Human Molecular Genetics, 2008, 17, 3720-3727.	2.9	61
96	An Oncogenomics-Based In Vivo RNAi Screen Identifies Tumor Suppressors in Liver Cancer. Cell, 2008, 135, 852-864.	28.9	404
97	Characterization of an acrosome protein VAD1.2/AEP2 which is differentially expressed in spermatogenesis. Molecular Human Reproduction, 2008, 14, 465-474.	2.8	8
98	Association of Mortalin (HSPA9) with Liver Cancer Metastasis and Prediction for Early Tumor Recurrence. Molecular and Cellular Proteomics, 2008, 7, 315-325.	3.8	152
99	The Kringle 1 Domain of Hepatocyte Growth Factor Has Antiangiogenic and Antitumor Cell Effects on Hepatocellular Carcinoma. Cancer Research, 2008, 68, 404-414.	0.9	31
100	Preimplantation Embryos Cooperate with Oviductal Cells to Produce Embryotrophic Inactivated Complement-3b. Endocrinology, 2008, 149, 1268-1276.	2.8	45
101	Serum Vascular Endothelial Growth Factor C Correlates With Lymph Node Metastases and High-Risk Tumor Profiles in Papillary Thyroid Carcinoma. Annals of Surgery, 2008, 247, 483-489.	4.2	64
102	Changes in Liver Histology as a "Surrogate―End Point of Antiviral Therapy for Chronic HBV Can Predict Progression to Liver Complications. Journal of Clinical Gastroenterology, 2008, 42, 533-538.	2.2	6
103	Silver Nanoparticles Inhibit Hepatitis B virus Replication. Antiviral Therapy, 2008, 13, 253-262.	1.0	489
104	Silver nanoparticles inhibit hepatitis B virus replication. Antiviral Therapy, 2008, 13, 253-62.	1.0	296
105	Genomic and proteomic biomarkers for diagnosis and prognosis of hepatocellular carcinoma. Biomarkers in Medicine, 2007, 1, 273-284.	1.4	19
106	Characterization of two novel LPSâ€binding sites in leukocyte integrin βA domain. FASEB Journal, 2007, 21, 3231-3239.	0.5	37
107	Artificial neural networks and decision tree model analysis of liver cancer proteomes. Biochemical and Biophysical Research Communications, 2007, 361, 68-73.	2.1	39
108	Serum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B. Journal of Hepatology, 2007, 47, 191-202.	3.7	52

#	Article	IF	CITATIONS
109	Hepatic stellate cell-targeted delivery of M6P-HSA-glycyrrhetinic acid attenuates hepatic fibrogenesis in a bile duct ligation rat model. Liver International, 2007, 27, 548-557.	3.9	43
110	Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: from laboratory discovery to clinical evaluation. Liver International, 2007, 27, 879-890.	3.9	109
111	Oncoproteomics of hepatocellular carcinoma: from cancer markers' discovery to functional pathways. Liver International, 2007, 27, 1021-1038.	3.9	48
112	Establishment and characterization of a new xenograft-derived human esophageal squamous cell carcinoma cell line HKESC-4 of Chinese origin. Cancer Genetics and Cytogenetics, 2007, 178, 17-25.	1.0	28
113	Clinicopathological Roles of Alterations of Tumor Suppressor Gene p16 in Papillary Thyroid Carcinoma. Annals of Surgical Oncology, 2007, 14, 1772-1779.	1.5	28
114	Altered E-Cadherin Expression and p120 Catenin Localization in Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2007, 14, 3260-3267.	1.5	52
115	Junction interaction in the seminiferous epithelium: regulatory roles of connexin-based gap junction. Frontiers in Bioscience - Landmark, 2007, 12, 1552.	3.0	30
116	Mutations in the Tight-Junction Gene Claudin 19 (CLDN19) Are Associated with Renal Magnesium Wasting, Renal Failure, and Severe Ocular Involvement. American Journal of Human Genetics, 2006, 79, 949-957.	6.2	446
117	Kinetics and Risk of De Novo Hepatitis B Infection in HBsAg–Negative Patients Undergoing Cytotoxic Chemotherapy. Gastroenterology, 2006, 131, 59-68.	1.3	440
118	Kidney claudinâ€19: Localization in distal tubules and collecting ducts and dysregulation in polycystic renal disease. FEBS Letters, 2006, 580, 923-931.	2.8	50
119	Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic Approach. Cell, 2006, 125, 1253-1267.	28.9	989
120	TNP-470 blockage of VEGF synthesis is dependent on MAPK/COX-2 signaling pathway in PDGF-BB-activated hepatic stellate cells. Biochemical and Biophysical Research Communications, 2006, 341, 239-244.	2.1	17
121	Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection. Journal of Clinical Virology, 2006, 35, 185-192.	3.1	42
122	The gene expression of adrenomedullin, calcitonin-receptor-like receptor and receptor activity modifying proteins (RAMPs) in CCl4-induced rat liver cirrhosis. Regulatory Peptides, 2006, 135, 69-77.	1.9	8
123	Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values. Proteomics, 2006, 6, 1049-1057.	2.2	177
124	MONOCLONAL ANTIBODIES AS TARGETING AND THERAPEUTIC AGENTS: PROSPECTS FOR LIVER TRANSPLANTATION, HEPATITIS AND HEPATOCELLULAR CARCINOMA. Clinical and Experimental Pharmacology and Physiology, 2006, 33, 482-488.	1.9	21
125	Blockage of testicular connexins induced apoptosis in rat seminiferous epithelium. Apoptosis: an International Journal on Programmed Cell Death, 2006, 11, 1215-1229.	4.9	72
126	Natural History of Patients with Recurrent Chronic Hepatitis C Virus and Occult Hepatitis B Co-Infection after Liver Transplantation American Journal of Transplantation, 2006, 6, 1600-1608.	4.7	21

#	Article	IF	CITATIONS
127	Acrosome-specific geneAEP1: Identification, characterization and roles in spermatogenesis. Journal of Cellular Physiology, 2006, 209, 755-766.	4.1	17
128	Increased Solubility of Integrin βA Domain Using Maltose-Binding Protein as a Fusion Tag. Protein and Peptide Letters, 2006, 13, 431-435.	0.9	7
129	Comparison of Real-Time PCR Assays for Monitoring Serum Hepatitis B Virus DNA Levels during Antiviral Therapy. Journal of Clinical Microbiology, 2006, 44, 2983-2987.	3.9	12
130	Liver Intestine-Cadherin ( <i>CDH17</i> ) Haplotype Is Associated with Increased Risk of Hepatocellular Carcinoma. Clinical Cancer Research, 2006, 12, 5248-5252.	7.0	34
131	Applicability of Tissue Aspirate for Quick Parathyroid Hormone Assay to Confirm Parathyroid Tissue Identity During Parathyroidectomy for Primary Hyperparathyroidism. Archives of Surgery, 2005, 140, 146.	2.2	19
132	Macrophage migration inhibitory factor expression correlates with inflammatory changes in human chronic hepatitis B infection. Liver International, 2005, 25, 571-579.	3.9	20
133	Hepatic potential of bone marrow stromal cells: Development of in vitro co-culture and intra-portal transplantation models. Journal of Immunological Methods, 2005, 305, 39-47.	1.4	80
134	CDX2 coâ€localizes with liver–intestine cadherin in intestinal metaplasia and adenocarcinoma of the stomach. Journal of Pathology, 2005, 205, 615-622.	4.5	37
135	Proteomic identification of Ku70/Ku80 autoantigen recognized by monoclonal antibody against hepatocellular carcinoma. Proteomics, 2005, 5, 1980-1986.	2.2	21
136	Increased Expression of Vascular Endothelial Growth Factor C in Papillary Thyroid Carcinoma Correlates with Cervical Lymph Node Metastases. Clinical Cancer Research, 2005, 11, 8063-8069.	7.0	102
137	High prevalence of cyclooxygenase 2 expression in papillary thyroid carcinoma. European Journal of Endocrinology, 2005, 152, 545-550.	3.7	30
138	Hepatocyte Growth Factor Promotes Cancer Cell Migration and Angiogenic Factors Expression: A Prognostic Marker of Human Esophageal Squamous Cell Carcinomas. Clinical Cancer Research, 2005, 11, 6190-6197.	7.0	138
139	Tumor necrosis factor- $\hat{l}$ ±-induced protein 1 and immunity to hepatitis B virus. World Journal of Gastroenterology, 2005, 11, 7564.	3.3	11
140	Identification of brain-derived neurotrophic factor as a novel functional protein in hepatocellular carcinoma. Cancer Research, 2005, 65, 219-25.	0.9	60
141	Alternative mRNA splicing of liver intestine-cadherin in hepatocellular carcinoma. Clinical Cancer Research, 2005, 11, 483-9.	7.0	52
142	Overâ€expression of inducible heat shock protein 70 in the gastric mucosa of partially sleepâ€deprived rats. Scandinavian Journal of Gastroenterology, 2004, 39, 510-515.	1.5	11
143	Different Testicular Gene Expression Patterns in the First Spermatogenic Cycle of Postnatal and Vitamin A-Deficient Rat Testis1. Biology of Reproduction, 2004, 70, 1010-1017.	2.7	7
144	Embryotrophic factor-3 from human oviductal cells enhances proliferation, suppresses apoptosis and stimulates the expression of the l²1 subunit of sodium–potassium ATPase in mouse embryos. Human Reproduction, 2004, 19, 2919-2926.	0.9	16

#	Article	IF	Citations
145	The Embryotrophic Activity of Oviductal Cell-derived Complement C3b and iC3b, a Novel Function of Complement Protein in Reproduction. Journal of Biological Chemistry, 2004, 279, 12763-12768.	3.4	78
146	Reduced Expression of Chemokine Receptors on Peripheral Blood Lymphocytes in Patients with Hepatocellular Carcinoma. American Journal of Gastroenterology, 2004, 99, 1111-1121.	0.4	26
147	Reply:. Hepatology, 2004, 39, 867-868.	<b>7.</b> 3	6
148	Overexpression of LI-cadherin in gastric cancer is associated with lymph node metastasis. Biochemical and Biophysical Research Communications, 2004, 319, 562-562.	2.1	0
149	Sp1 site is crucial for the mouse claudin-19 gene expression in the kidney cells. FEBS Letters, 2004, 578, 251-256.	2.8	25
150	Regulatory role of vHL/HIF- $1\hat{l}_{\pm}$ in hypoxia-induced VEGF production in hepatic stellate cells. Biochemical and Biophysical Research Communications, 2004, 317, 358-362.	2.1	69
151	Overexpression of LI-cadherin in gastric cancer is associated with lymph node metastasis. Biochemical and Biophysical Research Communications, 2004, 319, 562-568.	2.1	38
152	Expression of hepatocyte-like phenotypes in bone marrow stromal cells after HGF induction. Biochemical and Biophysical Research Communications, 2004, 320, 712-716.	2.1	107
153	The healing effects of Centella extract and asiaticoside on acetic acid induced gastric ulcers in rats. Life Sciences, 2004, 74, 2237-2249.	4.3	106
154	Recombinant adeno-associated virus vector: Is it ideal for gene delivery in liver transplantation?. Liver Transplantation, 2003, 9, 411-420.	2.4	4
155	Minimally invasive endoscopic-assisted parathyroidectomy for primary hyperparathyroidism. Surgical Endoscopy and Other Interventional Techniques, 2003, 17, 1932-1936.	2.4	21
156	Deregulation of E-cadherin-catenin complex in precancerous lesions of gastric adenocarcinoma. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 534-539.	2.8	34
157	Identification of liver–intestine cadherin in hepatocellular carcinoma—a potential disease marker. Biochemical and Biophysical Research Communications, 2003, 311, 618-624.	2.1	75
158	Identification of novel genes expressed during spermatogenesis in stage-synchronized rat testes by differential display. Biochemical and Biophysical Research Communications, 2003, 307, 782-790.	2.1	34
159	Embryotrophic Factor-3 from Human Oviductal Cells Affects the Messenger RNA Expression of Mouse Blastocyst1. Biology of Reproduction, 2003, 68, 375-382.	2.7	27
160	Long-term liver allograft survival induced by combined treatment with rAAV-hCTLA4lg gene transfer and low-dose FK5061. Transplantation, 2003, 75, 303-308.	1.0	15
161	Applicability of Intraoperative Parathyroid Hormone Assay During Thyroidectomy. Annals of Surgery, 2002, 236, 564-569.	4.2	124
162	Liver as an ideal target for gene therapy: Expression of CTLA4lg by retroviral gene transfer. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, 1008-1014.	2.8	26

#	Article	IF	Citations
163	Telomerase activity in small cell esophageal carcinoma. Ecological Management and Restoration, 2001, 14, 139-142.	0.4	24
164	Oesophageal basaloid squamous cell carcinoma: a unique clinicopathological entity with telomerase activity as a prognostic indicator. Journal of Pathology, 2001, 195, 435-442.	4.5	42
165	The clinicopathological features and importance of p53, Rb, and mdm2 expression in phaeochromocytomas and paragangliomas. Journal of Clinical Pathology, 2001, 54, 443-448.	2.0	42
166	Observations on Mortality during the 1918 Influenza Pandemic. Clinical Infectious Diseases, 2001, 33, 1375-1378.	5.8	131
167	Telomerase activity in pancreatic endocrine tumours: a potential marker for malignancy. Journal of Clinical Pathology, 2000, 53, 133-136.	1.9	23
168	Two Murine Monoclonal Antibodies against Serogroup E Salmonellae. Applied and Environmental Microbiology, 2000, 66, 419-421.	3.1	1
169	Immunosuppressive effects of Tripterygium wilfordii polysaccharide on LPS-Stimulated human monocytes. Transplantation Proceedings, 2000, 32, 2013-2015.	0.6	9
170	Differential suppression by tripterygium wilfordii extracts (traditional chinese medicine) in the allogeneic rat mixed lymphocyte reaction. Transplantation Proceedings, 2000, 32, 2055-2057.	0.6	5
171	Suppression of cytokine production and cell adhesion molecule expression in human monocytic cell line THP-1 by Tripterygium wilfordii polysaccharide moiety. Life Sciences, 2000, 67, 155-163.	4.3	34
172	Evaluation of Quantitative PCR and Branched-Chain DNA Assay for Detection of Hepatitis B Virus DNA in Sera from Hepatocellular Carcinoma and Liver Transplant Patients. Journal of Clinical Microbiology, 2000, 38, 1977-1980.	3.9	11
173	Telomerase Activity in Thyroid Malignancy. Thyroid, 1999, 9, 1215-1220.	4.5	31
174	Molecular biology of gastric carcinoma: From laboratory to bedside. Journal of Gastroenterology and Hepatology (Australia), 1999, 14, 1150-1160.	2.8	52
175	Differential expression of gap-junction gene connexin 31 in seminiferous epithelium of rat testes. FEBS Letters, 1999, 453, 243-248.	2.8	31
176	Signaling Mechanisms of Pertussis Toxin-Induced Myelomonocytic Cell Adhesion: Role of Tyrosine Phosphorylation. Biochemical and Biophysical Research Communications, 1997, 236, 479-482.	2.1	24
177	IN SITU GENE TRANSFER INTO RAT AUXILIARY LIVER TRANSPLANT1. Transplantation, 1997, 64, 1537-1541.	1.0	7
178	Immunochemical characterization of a haemagglutinating antigen of Arcobacterspp FEMS Microbiology Letters, 1996, 136, 209-213.	1.8	12
179	Immunochemical characterization of a haemagglutinating antigen of Arcobacter spp FEMS Microbiology Letters, 1996, 136, 209-213.	1.8	1
180	Biotinylated Lipopolysaccharide Binds to Endotoxin Receptor in Endothelial and Monocytic Cells. Analytical Biochemistry, 1995, 232, 217-224.	2.4	34

#	Article	IF	CITATIONS
181	Comparison of three stool-processing methods for detection of Salmonella serogroups B, C2, and D by PCR. Journal of Clinical Microbiology, 1994, 32, 3072-3074.	3.9	48
182	Detection of Enterobacterial Lipopolysaccharides and Experimental Endotoxemia by Means of an Immunolimulus Assay Using Both SerotypeSpecific and Cross-Reactive Antibodies. Journal of Infectious Diseases, 1993, 168, 393-399.	4.0	10
183	Selective amplification of abequose and paratose synthase genes (rfb) by polymerase chain reaction for identification of Salmonella major serogroups (A, B, C2, and D). Journal of Clinical Microbiology, 1993, 31, 2118-2123.	3.9	94
184	Specificity of monoclonal antibodies binding to the polysaccharide antigens (Vi, O9) of Salmonella typhi. FEMS Microbiology Letters, 1992, 97, 173-178.	1.8	5
185	Rapid and sensitive detection of Salmonella (0: 6,7) by immunomagnetic monoclonal antibody-based assays. Journal of Immunological Methods, 1991, 137, 1-8.	1.4	105
186	Anti-Salmonella lipopolysaccharide monoclonal antibodies: characterization of Salmonella BO-, CO-, DO-, and EO-specific clones and their diagnostic usefulness. Journal of Clinical Microbiology, 1991, 29, 2424-2433.	3.9	35
187	Efficient production of mouse and rat monoclonal antibodies against the O antigens of Salmonella serogroup C1, using LPS-coated bacteria as immunogen. Journal of Immunological Methods, 1990, 129, 243-250.	1.4	39
188	Characterisation and application of a murine monoclonal antibody specific for the serogroup C2 Salmonella. Journal of Medical Microbiology, 1988, 26, 115-119.	1.8	10
189	Murine monoclonal antibody specific for lipopolysaccharide of Salmonella serogroup A. Journal of Clinical Microbiology, 1987, 25, 2140-2144.	3.9	29